First Report of Sclerotinia homoeocarpa from the Sedge Trichophorum cespitosum in Eastern Canada, Which Causes Dollar Spot Disease on Lolium perenne and Poa pratensis but not on Agrostis stolonifera

Sclerotinia homoeocarpa is a fungal pathogen that causes dollar spot disease on more than 40 plant species, mostly in the family Poaceae (1), and is considered the most widespread pathogen of golf course turfgrasses in the St. Lawrence River Region. In June 2011, lesions were observed on tufted bulrush, Trichophorum cespitosum (Poales, Cyperaceae), on the sea shore near Peggys Cove, Nova Scotia, Canada. Single bunches had up to 40% of the leaves affected. The foliar symptoms resembled large hourglass lesions, up to 5 cm long, with a straw colored portion capped at two ends by dark zone lines on surrounding green foliar tissue. Leaf segments were taken, surface sterilized, and placed on potato dextrose agar (PDA). After 3 days of incubation at room temperature, white fluffy mycelia covered the entire petri dish. Brown columnar structures formed in the colony centers after 7 days and cultures became cinnamon colored after 14 days. Dark brown or black substratal stroma were formed on or in the agar, and cultures appeared dark brown from the bottom. DNA was extracted and amplified using primers ITS1 and ITS4 (2), and the amplicon sequenced (GenBank Accession No. KF447776). The sequence showed a top match of 522/524 bp identity with the ITS of an isolate of S. homoeocarpa, with the next 40 top matches also identified as S. homoeocarpa. Two-week-old seedlings of Agrostis stolonifera cv. Penncross, Poa pratensis cv. Touchdown, and Lolium perenne cv. Express were inoculated by placing 5-mm-diameter mycelial plugs from 5-day-old PDA cultures onto the leaves of plants grown in small containers, and incubating under enclosed humid conditions throughout the test. White aerial hyphae on the leaves and straw-colored leaf lesions were observed by 7 days after inoculation on P. pratensis and L. perenne, but no lesions or hyphal growth were observed on A. stolonifera. No signs or symptoms were observed on leaves where sterile agar plugs were used as inoculum. These tests were repeated three times with the same results, and a positive control was included by using an S. homoeocarpa isolate known to be pathogenic to A. stolonifera under the same test conditions. Disease was observed on A. stolonifera with the control isolate. S. homoeocarpa was re-isolated from the lesions on P. pratensis and L. perenne to satisfy Koch's postulates. To the best of our knowledge, this is the first report of S. homoeocarpa on T. cespitosum worldwide, an isolate that was found to cause disease on P. pratensis and L. perenne, but was not pathogenic to A. stolonifera in vitro. The original host was not used in pathogenicity tests because it is considered an endangered species in many locations. References: (1) B. Walsh et al. HortScience 34:13, 1999. (2) T. J. White et al. PCR protocols, a guide to methods and applications 18:315, 1990.

Nuclear magnetic resonance spectroscopy on a (5-nanometer)3 sample volume

Application of nuclear magnetic resonance (NMR) spectroscopy to nanoscale samples has remained an elusive goal, achieved only with great experimental effort at subkelvin temperatures. We demonstrated detection of NMR signals from a (5-nanometer)(3) voxel of various fluid and solid organic samples under ambient conditions. We used an atomic-size magnetic field sensor, a single nitrogen-vacancy defect center, embedded ~7 nanometers under the surface of a bulk diamond to record NMR spectra of various samples placed on the diamond surface. Its detection volume consisted of only 10(4) nuclear spins with a net magnetization of only 10(2) statistically polarized spins.

Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene

Activation of the transcription factor signal transducer and activator of transcription 5b (STAT5b) is a key event in the development of asthma. The potent ability of small interfering RNA (siRNA) to inhibit the expression of STAT5b mRNA has provided a new class of therapeutics for asthma. However, efficient delivery of siRNAs remains a key obstacle to their successful application. A targeted intracellular delivery approach for siRNA to specific cell types would be highly desirable. We used packaging RNA (pRNA), a component of the bacteriophage phi29-packaging motor, to deliver STAT5b siRNA to asthmatic spleen lymphocytes. This pRNA was able to spontaneously carry siRNA/STAT5b and aptamer/CD4, which is a ligand to CD4 molecule. Based on RT-PCR data, the pRNA dimer effectively inhibited STAT5b gene mRNA expression of asthmatic spleen lymphocytes, without the need for additional transfections. We conclude that the pRNA dimer carrying both siRNA and aptamer can deliver functional siRNA to cells; possibly, the aptamer acts as a ligand to interact with specific receptors. The pRNAs were evaluated with a CCK-8 kit and were found to have little cytotoxicity. We conclude that pRNA as a novel nanovehicle for RNA worth further study.

First Report of Leaf Spot of Kentucky Bluegrass (Poa pratensis) Caused by Nigrospora oryzae in Ontario

Kentucky bluegrass (Poa pratensis L.) is an important cool-season perennial grass in Ontario. It is native to Europe and can form an attractive and durable turf. In late September 2011, distinct leaf spots were observed on a Kentucky bluegrass lawn in Guelph, ON. Symptoms ranged from small lesions that were chocolate brown and oval or circular up to withered leaves. On potato dextrose agar (PDA) amended with streptomycin and tetracycline, a fungus was consistently recovered from symptomatic leaf samples after surface sterilization for 1 min in 1% sodium hypochlorite. On PDA, cultures were gray with an irregularly distributed, wool-like, fastgrowing aerial mycelium, showing a dark back side as the colony changed to darker brown after 7 days at 25°C. On diseased leaves, conidia were observed after moist incubation, borne on a hyaline vesicle at the tip of each conidiophore. Conidia were single celled, black, smooth, spherical, and 11.2 to 15.5 μm (average 13.8 μm) in diameter. The pathogen was identified as Nigrospora oryzae based on previous descriptions (1,2). Genomic DNA was extracted from a representative isolate, 11201, and the internal transcribed spacer (ITS) region of the ribosomal DNA was amplified by the primers ITS1 and ITS4 (4). The ITS sequence showed 99.8% similarity in the overlapping 508-bp portion with N. oryzae (GenBank No. GQ328855). Pathogenicity tests were performed in the laboratory with the isolate on 3-week-old, sand-based, Magenta box-grown plants of three cool-season turfgrass species, P. pratensis, Agrostis stolonifera, and Lolium perenne, by inoculating with fungal plugs. A 5-mm-diameter plug from 5-day-old PDA cultures was directly placed onto leaves in each of four replicate boxes per species, and then removed after 48 h of incubation. Plants treated with sterile agar plugs served as controls. Magenta boxes containing treated turf were covered loosely with their plastic lids and incubated at 23°C. Three days after inoculation and 1 day after inoculum removal, typical chocolate brown spots were observed on inoculated leaves from all three turfgrass species, but no symptoms were seen on agar plug-treated control plants. Koch's postulates were fulfilled by reisolation of N. oryzae from diseased leaves. The pathogenicity tests were carried out twice with the same results. This is an indication that N. oryzae causing leaf spot of Kentucky bluegrass in Ontario was not hostspecific, and could potentially affect other cool-season turfgrass species. Review of the literature revealed that N. oryzae is known as a pathogen on maize, rice, sorghum, cotton, weeds, and several other hosts, but has not been reported on any species of turfgrass (3). To our knowledge, this is the first report of N. oryzae infecting Kentucky bluegrass in Ontario or worldwide. References: (1) M. B. Ellis. Dematiaceous Hyphomycetes, CAB, Kew, Surrey, England, 1971. (2) H. J. Hudson. Trans. Brit. Mycol. Soc. 46:355, 1963. (3) R. W. Smiley et al. Compendium of Turfgrass Diseases. 3rd ed. APS Press, St Paul, MN, 2005. (4) T. J. White et al. PCR Protocols: A Guide to Methods and Applications. Academic Press, San Diego, 1990.

Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome

Recent studies showed that an imbalance of prothrombotic and antithrombotic factors and impaired thrombolytic activity contribute to the thrombophilia of the nephrotic syndrome (NS). However, it is not clear whether blood cell injury and/or activation is involved in hypercoagulability in NS patients. Our objectives were to study the increase in microparticle (MP) release and phosphatidylserine (PS) exposure on the outer membrane of MP-origin cells in NS patients, and to evaluate their procoagulant activity (PCA). The subjects were patients with membranous nephropathy (MN), minimal change nephrotic syndrome (MCNS) and healthy controls. Analyses of MPs and PS exposure were performed using a flow cytometer. PCA was determined by clotting time and purified coagulation complex assays. We found that lactadherin+ MPs, which derived from red blood cells (RBC), platelet and endothelial cell, increased in NS patients. Moreover, PS exposure on RBCs and platelets in each NS group, especially in MN, are higher than that in controls. MP shedding and PS exposure of RBCs/platelets were highly procoagulant in NS patients. However, blockade of PS with lactadherin inhibited over 90% of PCA while an anti-tissue factor antibody had no significant inhibition effect. Our results demonstrate that the thrombophilic susceptibility of NS may be partly ascribed to MP release and PS exposure of RBCs, platelets and endothelial cells. Lactadherin is a sensitive probe for PS that has high anticoagulant activity.

Neutralizing CCL2 Inhibits Breast Tumor Growth Via Impact on the Tumor/Stroma Microenvironment

CCL2, (CC-chemokine ligand 2 or monocyte chemoattractant protein-1 (MCP-1)), is overexpressed in many human tumors and is believed to exert pro-tumor effects by recruiting monocytes to the tumor, where these cells become tumor associated macrophages (TAMs). TAMs secrete growth factors that stimulate angiogenesis and tumor growth, as well as proteases to promote tumor invasion and metastasis. CCL2 expression levels in primary breast tumors have been correlated with macrophage infiltration and blood vessel density, which in turn is correlated with disease stage and prognosis. These correlations indicate that CCL2 is a key player in tumor macrophage infiltration and/or tumor growth/invasion, and suggest that neutralizing CCL2 could be an effective form of therapy for breast cancer patients.The objective of these studies was to investigate whether CCL2 blockade could inhibit tumor growth in mice bearing human breast tumors. The human breast tumor cell lines MDA-MB-231 (ER-, PR-, Her2-) and MDA-MB-361 (ER+, PR+, Her2+) were implanted orthotopically in immunocompromised mice, and in both models the primary tumors metastasized to lungs and brain. Neutralizing antibodies to human CCL2 (CNTO 888) and to the mouse orthologs, MCP-1 and MCP-5, were administered therapeutically, either as a cocktail (termed CCL2 blockade) or individually to study the relative roles of host vs tumor derived CCL2 in promoting tumor growth.In both tumor models, CCL2 blockade significantly inhibited the growth of established primary tumors in the mammary fat pad. In addition, CCL2 blockade inhibited metastasis to distant sites. As measured by Taqman, visual inspection and immunohistochemistry, mice with MDA-MB-361 tumors treated with CCL2 blockade showed significantly reduced metastasis to lungs and brain, while mice bearing MDA-MB-231 tumors showed significantly reduced metastasis to lungs.To define the relative roles of human tumor-derived CCL2 vs mouse host-derived MCP-1/MCP-5, in vivo monotherapy tumor studies were conducted using the individual neutralizing antibodies. These studies included the mammary fat pad model and a tail vein metastasis model. In both cases, only the treatment with the anti-mouse MCP-1 antibody significantly inhibited primary tumor growth and distant metastasis, indistinguishable from the effect of CCL2 blockade treatment. In the tail vein metastasis model, the antibody treatment resulted in significantly fewer detectable lesions with these lesions showing a significant reduction in both tumor size and growth fraction, suggesting antibody treatment inhibits tumor seeding and growth. Mechanistic studies are in progress to further understand the basis of the anti-tumor effect mediated by the antibody treatment. These results demonstrate that host-derived MCP-1, produced from the tumor microenvironment, plays the critical role in tumor growth and metastasis in these models of human breast cancer.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6095.